The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Fedorova N.V.

Russian Medical Academy of Continuous Professional Education

Bril E.V.

Burnazyan Federal Medical and Biophysical Center

Kulua T.K.

Russian Medical Academy of Continuous Professional Education

Mikhaylova A.D.

Russian State Research Center — Burnasyan Federal Medical Biophysical Center

Progressive supranuclear palsy

Authors:

Fedorova N.V., Bril E.V., Kulua T.K., Mikhaylova A.D.

More about the authors

Read: 25836 times


To cite this article:

Fedorova NV, Bril EV, Kulua TK, Mikhaylova AD. Progressive supranuclear palsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(5):111‑119. (In Russ.)
https://doi.org/10.17116/jnevro2021121051111

Recommended articles:
Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34
Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99
A portrait of a doctor with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):160-164
Pathomorphosis of the Parkinson’s disease against the background of DBS STN. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):21-27
Neuroinflammatory and neurodegenerative aspe­cts of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):102-111

References:

  1. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333-359.  https://doi.org/10.1001/archneur.1964.00460160003001
  2. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, Holton JL, Revesz T, Lees AJ. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain. 2005;128(Pt 6):1247-1258. https://doi.org/10.1093/brain/awh488
  3. Nath U, Ben-Shlomo Y, Thomson RG, Morris HR, Wood NW, Lees AJ, Burn DJ. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain. 2001;124(Pt 7):1438-49. PMID: 11408338. https://doi.org/10.1093/brain/124.7.1438
  4. Takigawa H, Kitayama M, Wada-Isoe K, Kowa H, Nakashima K. Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade. Brain Behav. 2016;6(12):e00557. https://doi.org/10.1002/brb3.557
  5. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999;354(9192):1771-1775. https://doi.org/10.1016/s0140-6736(99)04137-9
  6. Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, McKee A, Dickson D, Bancher C, Tabaton M, Jellinger K, Anderson DW. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol. 1996;55(1):97-105.  https://doi.org/10.1097/00005072-199601000-00010
  7. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1-9.  https://doi.org/10.1212/wnl.47.1.1
  8. Litvan I, Mangone CA, McKee A, Verny M, Parsa A, Jellinger K, D’Olhaberriague L, Chaudhuri KR, Pearce RK. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1996;60(6):615-620.  https://doi.org/10.1136/jnnp.60.6.615
  9. Chen AL, Riley DE, King SA, Joshi AC, Serra A, Liao K, Cohen ML, Otero-Millan J, Martinez-Conde S, Strupp M, Leigh RJ. The disturbance of gaze in progressive supranuclear palsy: implications for pathogenesis. Front Neurol. 2010;1:147.  https://doi.org/10.3389/fneur.2010.00147
  10. Soliveri P, Piacentini S, Girott F. Limb apraxia and cognitive impairment in progressive supranuclear palsy. Neurocase. 2005;11(4):263-267.  https://doi.org/10.1080/13554790590962988
  11. Gerstenecker A, Duff K, Mast B, Litvan I. Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Research. 2013;210(3):1205-1210. https://doi.org/10.1016/j.psychres.2013.08.045
  12. Radicati FG, Martinez Martin P, Fossati C, Chaudhuri KR, Torti M, Rodriguez Blazquez C, Vacca L, Stocchi F. Non motor symptoms in progressive supranuclear palsy: prevalence and severity. NPJ Parkinsons Dis. 2017;3:35.  https://doi.org/10.1038/s41531-017-0037-x
  13. Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I; Movement Disorder Society-endorsed PSP Study Group. Clinical Diagnosis of Progressive Supranuclear Palsy — The Movement Disorder Society Criteria. Mov Disord. 2017;32(6):853-864.  https://doi.org/10.1002/mds.26987
  14. Litvan I, Campbell G, Mangone CA, Verny M, McKee A, Chaudhuri KR, Jellinger K, Pearce RK, D’Olhaberriague L. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain. 1997;120(1):65-74.  https://doi.org/10.1093/brain/120.1.65
  15. Lopez OL, Litvan I, Catt KE, Stowe R, Klunk W, Kaufer DI, Becker JT, DeKosky ST. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology. 1999;53(6):1292-1299. https://doi.org/10.1212/wnl.53.6.1292
  16. Osaki Y, Ben-Shlomo Y, Lees AJ, Daniel SE, Colosimo C, Wenning G, Quinn N. Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord. 2004;19(2):181-189.  https://doi.org/10.1002/mds.10680
  17. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2009;8(3):270-279.  https://doi.org/10.1016/S1474-4422(09)70042-0
  18. Ling H. Clinical Approach to Progressive Supranuclear Palsy. Mov Disord. 2016;9(1):3-13.  https://doi.org/10.14802/jmd.15060
  19. Boxer AL, Garbutt S, Seeley WW, Jafari A, Heuer HW, Mirsky J, Hellmuth J, Trojanowski JQ, Huang E, DeArmond S, Neuhaus J, Miller BL. Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease. Arch of Neurology. 2012;69(4):509-517.  https://doi.org/10.1001/archneurol.2011.1021
  20. Levin OS. Kak lechit parkinsonism ne pri bolezni Parkinsona? Trudnyj Pacient. 2008;5-6(6):29-37. (In Russ.).
  21. Ekstrapiramidnye rasstrojstva. Rukovodstvo po diagnostike I lecheniyu. Pod red. Shtoka N.V., Ivanovoj-Smolenskoj I.A., Levina O.S. M.:MED-Pressinform; 2002. (In Russ.).
  22. Stamelou M, Quinn NP, Bhatia KP. «Atypical» Atypical Parkinsonism : New Genetic Conditions Presenting With Features of Progressive Supranuclear Palsy, Corticobasal Degeneration, or Multiple System Atrophy — A Diagnostic Guide General Considerations and Scope. Mov Disord. 2013;28(9):1184-1199. https://doi.org/10.1002/mds.25509
  23. Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord. 2010;25(3):357-362.  https://doi.org/10.1002/mds.22977
  24. Santos-Santos MA, Mandelli ML, Binney RJ, Ogar J, Wilson SM, Henry ML, Hubbard HI, Meese M, Attygalle S, Rosenberg L, Pakvasa M, Trojanowski JQ, Grinberg LT, Rosen H, Boxer AL, Miller BL, Seeley WW, Gorno-Tempini ML. Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration. JAMA Neurol. 2016;73(6):733-742.  https://doi.org/10.1001/jamaneurol.2016.0412
  25. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for ebehavioural variant of frontotemporal dementia. Brain. 2011;134(9):2456-2477. https://doi.org/10.1093/brain/awr179
  26. Koga S, Josephs KA, Ogaki K, Labbé C, Uitti RJ, Graff-Radford N, van Gerpen JA, Cheshire WP, Aoki N, Rademakers R, Wszolek ZK, Ross OA, Dickson DW.Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSP-C. Mov Disord. 2016;31(5):653-662.  https://doi.org/10.1002/mds.26499
  27. Mcfarland NR. Diagnostic Approach to Atypical Parkinsonian Syndromes. Neurology. 2016;22(4):1117-1142. https://doi.org/10.1212/con.0000000000000348
  28. Respondek G, Stamelou M, Kurz C, Ferguson LW, Rajput A, Chiu WZ, van Swieten JC, Troakes C, Al Sarraj S, Gelpi E, Gaig C, Tolosa E, Oertel WH, Giese A, Roeber S, Arzberger T, Wagenpfeil S, Höglinger GU; Movement Disorder Society-endorsed PSP Study Group. The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases. Mov Disord. 2014;29(14):1758-1766. https://doi.org/10.1002/mds.26054
  29. O’Sullivan SS, Massey LA, Williams DR, Silveira-Moriyama L, Kempster PA, Holton JL, Revesz T, Lees AJ. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 2008;131(5):1362-1372. https://doi.org/10.1093/brain/awn065
  30. Caparros-Lefebvre D, Sergeant N, Lees A, Camuzat A, Daniel S, Lannuzel A, Brice A, Tolosa E, Delacourte A, Duyckaerts C. Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain. 2002;125(4):801-811.  https://doi.org/10.1093/brain/awf086
  31. Ando S, Kanazawa M, Onodera O. Progressive Supranuclear Palsy with Predominant Cerebellar Ataxia. Mov Disord. 2020;13(1):20-26.  https://doi.org/10.14802/jmd.19061
  32. Williams DR, Pittman AM, Revesz T, Lees AJ, de Silva R. Genetic variation at the tau locus and clinical syndromes associated with progressive supranuclear palsy. Mov Disord. 2007;22(6):895-897.  https://doi.org/10.1002/mds.21393
  33. Josephs KA, Mandrekar JN, Dickson DW. The relationship between histopathological features of progressive supranuclear palsy and disease duration. Parkinsonism Relat Disord. 2006;12(2):109-112.  https://doi.org/10.1016/j.parkreldis.2005.08.007
  34. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain. 2007;130(6):1552-1565. https://doi.org/10.1093/brain/awn032
  35. Illarioshkin SN. Konformacionnye bolezni mozga. M.: Yanus-K. (In Russ.).
  36. Pollock NJ, Mirra SS, Binder LI, Hansen LA, Wood JG. Filamentous aggregates in Pick’s disease, progressive supranuclear palsy, and Alzheimer’s disease share antigenic determinants with microtubule-associated protein, tau. Lancet. 1986;328(8517):1211. https://doi.org/10.1016/s0140-6736(86)92212-9
  37. Chen S, Townsend K, Goldberg TE, Davies P, Conejero-Goldberg C. MAPT Isoforms: Differential Transcriptional Profiles Related to 3R and 4R Splice Variants. Alzheimers Dis. 2010;22(4):1313-1329. https://doi.org/10.3233/jad-2010-101155
  38. Stamelou M, de Silva R, Arias-Carrión O, Boura E, Höllerhage M, Oertel WH, Müller U, Höglinger GU. Rational therapeutic approaches to progressive supranuclear palsy. Brain. 2010;133(6):1578-1590. https://doi.org/10.1093/brain/awq115
  39. Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010;23(4):394-400.  https://doi.org/10.1097/WCO.0b013e32833be924
  40. McFarland NR. Diagnostic Approach to Atypical Parkinsonian Syndromes. Mov Disod. 2016;22(4):1117-1142. https://doi.org/10.1212/con.0000000000000348
  41. Golbe LI. The epidemiology of progressive supranuclear palsy. Adv Neurol. 1996;69:25-31. 
  42. Tolosa E, Valldeoriola F, Marti MJ. Clinical diagnosis and diagnostic of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neural Transm Suppl. 1994;42:15-31.  https://doi.org/10.1007/978-3-7091-6641-3_2
  43. Massey LA, Micallef C, Paviour DC, O’Sullivan SS, Ling H, Williams DR, Kallis C, Holton JL, Revesz T, Burn DJ, Yousry T, Lees AJ, Fox NC, Jäger HR. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2012;27(14):1754-1762. https://doi.org/10.1002/mds.24968
  44. Massey LA, Jäger HR, Paviour DC, O’Sullivan SS, Ling H, Williams DR, Kallis C, Holton J, Revesz T, Burn DJ, Yousry T, Lees AJ, Fox NC, Micallef C. The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology. 2013;80(20):1856-1861. https://doi.org/10.1212/WNL.0b013e318292a2d2
  45. Gardner RC, Boxer AL, Trujillo A, Mirsky JB, Guo CC, Gennatas ED, Heuer HW, Fine E, Zhou J, Kramer JH, Miller BL, Seeley WW.Intrinsic connectivity network disruption in progressive supranuclear palsy. Ann Neurol. 2013;73(5):603-616.  https://doi.org/10.1002/ana.23844
  46. Botha H, Whitwell JL, Madhaven A, Senjem ML, Lowe V, Josephs KA. The pimple sign of progressive supranuclear palsy syndrome. Parkinsonism Relat Disord. 2014;20(2):180-185.  https://doi.org/10.1016/j.parkreldis.2013.10.023
  47. Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81(1):5-12.  https://doi.org/10.1136/jnnp.2008.157370
  48. Orimo S, Suzuki M, Inaba A, Mizusawa H.. 123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2012;18(5):494-500.  https://doi.org/10.1016/j.parkreldis.2012.01.009
  49. Vlaar AM, de Nijs T, Kessels AG, Vreeling FW, Winogrodzka A, Mess WH, Tromp SC, van Kroonenburgh MJ, Weber WE.Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol. 2008;59(5):258-266.  https://doi.org/10.1159/000115640
  50. Whitwell JL, Master AV, Avula R, Kantarci K, Eggers SD, Edmonson HA, Jack CR Jr, Josephs KA. Clinical correlates of white matter tract degeneration in progressive supranuclear palsy. Arch Neurol. 2011;68(6):753-760.  https://doi.org/10.1001/archneurol.2011.107
  51. Dani M, Brooks DJ, Edison P. Tau imaging in neurodegenerative diseases. Eur J Nucl Med Mol Imaging. 2016;43(6):1139-1150. https://doi.org/10.1007/s00259-015-3231-2
  52. Marquié M, Normandin MD, Meltzer AC, Siao Tick Chong M, Andrea NV, Antón-Fernández A, Klunk WE, Mathis CA, Ikonomovic MD, Debnath M, Bien EA, Vanderburg CR, Costantino I, Makaretz S, DeVos SL, Oakley DH, Gomperts SN, Growdon JH, Domoto-Reilly K, Lucente D, Dickerson BC, Frosch MP, Hyman BT, Johnson KA, Gómez-Isla T. Pathologic correlations of F-18-AV-1451 imaging in non-Alzheimer tauopathies. Ann Neurol. 2017;81(1):117-128.  https://doi.org/10.1002/ana.24844
  53. Passamonti L, Vázquez Rodríguez P, Hong YT, Allinson KS, Williamson D, Borchert RJ, Sami S, Cope TE, Bevan-Jones WR, Jones PS, Arnold R, Surendranathan A, Mak E, Su L, Fryer TD, Aigbirhio FI, O’Brien JT, Rowe JB. 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy. Brain. 2017;140(3)781-791.  https://doi.org/10.1093/brain/aww340
  54. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10(3):230-240.  https://doi.org/10.1016/S1474-4422(11)70014-X
  55. Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P; PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics. 2011;43(7):699-705.  https://doi.org/10.1038/ng.859
  56. Litvan I, Lees PS, Cunningham CR, Rai SN, Cambon AC, Standaert DG, Marras C, Juncos J, Riley D, Reich S, Hall D, Kluger B, Bordelon Y, Shprecher DR; for ENGENE-PSP. Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study. Mov Disord. 2016;31(5):644-652.  https://doi.org/10.1002/mds.26512
  57. Lawrence I. Golbe. The Tau of PSP: A Long Road to Treatment. Mov Disord. 2014;29(4):431-434.  https://doi.org/10.1002/mds.25855
  58. Lamb R, Rohrer JD, Lees AJ, Morris HR. Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options. Curr Treat Options Neurol. 2016;18(9):42.  https://doi.org/10.1007/s11940-016-0422-5
  59. Apetauerova D, Scala SA, Hamill RW, Simon DK, Pathak S, Ruthazer R, Standaert DG, Yacoubian TA. CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e266. https://doi.org/10.1212/NXI.0000000000000266
  60. Hughes LE, Rittman T, Regenthal R, Robbins TW, Rowe JB. Improving response inhibition systems in frontotemporal dementia with citalopram. Brain. 2015;138(7):1961-1975. https://doi.org/10.1093/brain/awv133
  61. Piccione F, Mancini E, Tonin P, Bizzarini M. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Arch Phys Med Rehabil. 1997;78(5):525-529.  https://doi.org/10.1016/s0003-9993(97)90169-6
  62. Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU.The Differential Diagnosis and Treatment of Atypical Parkinsonism. Dtsch Arztebl Int. 2016;113(5):61-90.  https://doi.org/10.3238/arztebl.2016.0061
  63. Scelzo E, Lozano AM, Hamani C, Poon YY, Aldakheel A, Zadikoff C, Lang AE, Moro E. Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. J Neurol Neurosurg Psychiatry. 2017;88(7):613-616.  https://doi.org/10.1136/jnnp-2016-315192
  64. Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN; NNIPPS Study Group. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009;132(1):156-171.  https://doi.org/10.1093/brain/awn291
  65. Tolosa E, Litvan I, Höglinger GU, Burn D, Lees A, Andrés MV, Gómez-Carrillo B, León T, Del Ser T; TAUROS Investigators. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29(4):470-478.  https://doi.org/10.1002/mds.25824
  66. Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR Jr, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH; AL-108-231 Investigators. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13(7):676-685.  https://doi.org/10.1016/S1474-4422(14)70088-2
  67. Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, Miller TM, Grinberg LT, Seeley WW, Diamond MI. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82(6):1271-1288. https://doi.org/10.1016/j.neuron.2014.04.047
  68. Kondo A, Shahpasand K, Mannix R, Qiu J, Moncaster J, Chen CH, Yao Y, Lin YM, Driver JA, Sun Y, Wei S, Luo ML, Albayram O, Huang P, Rotenberg A, Ryo A, Goldstein LE, Pascual-Leone A, McKee AC, Meehan W, Zhou XZ, Lu KP. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature. 2015;523(7561):431-436.  https://doi.org/10.1038/nature14658

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.